Showing posts with label Depression. Show all posts
Showing posts with label Depression. Show all posts

January 30, 2015

Friday, January 30, 2015
New research in Canada reveals that inflammation deep in the brain may be linked to depression.  Specifically, the Centre for Addiction and Mental Health (CAMH) studied the brain scans of patients with depression and those without.  Results showed 30% more inflammation in the brains of patients with clinical depression.  In addition, symptoms worsened with the degree of inflammation.  Keeping in mind that researchers only studied the scans of 40 patients, concrete conclusions are a tad premature.

Nevertheless, this research does offer new ideas for investigation, which could uncover other possible causes for the illness as well as potential new treatments for depression.  In other words, perhaps reducing inflammation in the brain may alleviate or eliminate the symptoms.  This is exciting news for the individuals that do not respond to medication, which, according to this research, consists of 30 to 50 per cent of patients!
“Inflammation is part of the complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants.
[…] The purpose of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and to initiate tissue repair.
[…] Too little inflammation could lead to progressive tissue destruction by the harmful stimulus (eg. bacteria) and compromise the survival of the organism. In contrast, chronic inflammation may lead to a host of diseases, such as hay fever, periodontitis, atherosclerosis, rheumatoid arthritis, and even cancer (e.g., gallbladder carcinoma).”
According to Dr. Jeffrey Meyer of CAMH, it is theorized that the body of patients that have suffered some type of infection or trauma may have healed, however the brain has not had the opportunity to recover.  This may explain why patients with certain types of inflammatory disease, such as lupus, are several times more likely to develop clinical depression.

Of course, it is still unclear whether the inflammation in the brain occurs before depression sets in or as a result of the illness.
_______________________________________________

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called major depression, major depressive disorder or clinical depression, it affects how you feel, think and behave and can lead to a variety of emotional and physical problems. You may have trouble doing normal day-to-day activities, and depression may make you feel as if life isn't worth living.

During these episodes, symptoms occur most of the day, nearly every day and may include:
  • Feelings of sadness, emptiness or unhappiness
  • Angry outbursts, irritability or frustration, even over small matters
  • Loss of interest or pleasure in normal activities, such as sex
  • Sleep disturbances, including insomnia or sleeping too much
  • Tiredness and lack of energy, so that even small tasks take extra effort
  • Changes in appetite — often reduced appetite and weight loss, but increased cravings for food and weight gain in some people
  • Anxiety, agitation or restlessness — for example, excessive worrying, pacing, hand-wringing or an inability to sit still
  • Slowed thinking, speaking or body movements
  • Feelings of worthlessness or guilt, fixating on past failures or blaming yourself for things that are not your responsibility
  • Trouble thinking, concentrating, making decisions and remembering things
  • Frequent thoughts of death, suicidal thoughts, suicide attempts or suicide
  • Unexplained physical problems, such as back pain or headaches
Facts: 
  • Depression is a common mental disorder. Globally, more than 350 million people of all ages suffer from depression.
  • Depression is the leading cause of disability worldwide, and is a major contributor to the global burden of disease.
  • More women are affected by depression than men.
  • At its worst, depression can lead to suicide.
  • There are effective treatments for depression.
Study finds link between depression, brain inflammation
Inflammation
Depression (major depressive disorder)
Depression

© www.mentalhealthblog.com

January 19, 2013

Saturday, January 19, 2013

Research shows that the use of choline supplements during pregnancy may prevent schizophrenia.  Specifically, lower rates of physiological schizophrenic risk factors in infants 33 days old has been noted when the dietary supplement is given during the second and third trimesters of pregnancy and early infancy.

Robert Freedman, MD, professor and chairman of the Department of Psychiatry, University of Colorado School of Medicine and one of the study's authors states: "Basic research indicates that choline supplementation during pregnancy facilitates cognitive functioning in offspring. Our finding that it ameliorates some of the pathophysiology associated with risk for schizophrenia now requires longer-term follow-up to assess whether it decreases risk for the later development of illness as well."

Choline is a water-soluble essential nutrient, typically grouped within the B-complex vitamins. It can be found naturally in foods such as liver, muscle meats, fish, nuts and eggs.  According to the American Institute of Medicine, pregnant women require between 450 and 3500 milligrams of choline each day and 550 to 3500 milligrams while lactating.  Infants aged 0-6 months need a minimum daily dose of 125 milligrams of choline and 150 milligrams from 7-12 months of age.

“Choline is also being studied for potential benefits in liver disease, including chronic hepatitis and cirrhosis, depression, memory loss, Alzheimer's disease and dementia, and certain types of seizures.”

To test their theory, researchers observed infant responses to a clicking sound.  Typically, the brain responds fully to an initial click, however the response to a second click immediately following the first is inhibited.  This trait is often absent among schizophrenia patients and relates to poor sensory filtering and familial transmission of schizophrenia risk.  Researchers observed this effect among infants to represent the illness as schizophrenia does not normally appear until adolescence.

“Half the healthy pregnant women in this study took 3,600 milligrams of phosphatidylcholine each morning and 2,700 milligrams each evening; the other half took placebo. After delivery, their infants received 100 milligrams of phosphatidylcholine per day or placebo. Eighty-six percent of infants exposed to pre- and postnatal choline supplementation, compared to 43% of unexposed infants, inhibited the response to repeated sounds, as measured with EEG sensors placed on the baby's head during sleep.”

These results could not only assist in early detection of schizophrenia, but may even help in preventing the illness or developing more effective treatments.

Some examples of choline found in different food sources:

Type of Food
mg of choline
5 ounces (142 g) raw beef liver
473
Large hardboiled egg
113
Half a pound (227 g) cod fish
190
Half a pound of chicken
150
Quart of milk, 1% fat
173
A gram soy lecithin
30
100 grams of Soybeans dry
116
A pound (454 grams) of cauliflower
177
A pound of spinach
113
A cup of wheat germ
202
Two cups (0.47 liters) firm tofu
142
Two cups of cooked kidney beans
108
A cup of uncooked quinoa
119
A cup of uncooked amaranth
135
A grapefruit
19
Three cups (710 cc) cooked brown rice
54
A cup (146 g) of peanuts
77
A cup (143 g) of almonds
74

Choline Supplementation DuringPregnancy Presents a New Approach to Schizophrenia Prevention
Choline

November 9, 2011

Wednesday, November 09, 2011
Research reveals that people that experience recurring episodes of depression or those that are exposed to chronic stress have shorter telomeres in their white blood cells.

“A telomere is a region of repetitive DNA sequences at the end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes.” Consequently, as we age, telomeres, the outermost part of the chromosome, shorten.

Moreover, research suggests that oxidative stress and inflammation can accelerate this process. The lengths of telomeres are suggestive of our biological age and have been associated with age-related diseases, unhealthy lifestyle, and longevity. Additionally, new studies now show that the shortening of telomeres is also linked to recurrent depression and exposure to chronic stress.

To demonstrate, researchers studied 91 patients with recurrent depression and 451 healthy patients by measuring the telomere length in their white blood cells.

Results showed that telomeres were shorter among the patients with recurrent depression. Also, by examining the participants' stress regulation using a dexamethasone suppression test, researchers again revealed that cortisol levels, indicative of chronic stress, were also associated with shorter telomeres in both depressed participants and healthy ones.

“The fact that depressed patients as a group have shorter telomere lengths compared to healthy individuals can be largely explained by the fact that more depressed people than healthy people have disturbed cortisol regulation, which underscores that cortisol regulation and stress play a major role in depressive disorders” says Mikael Wikgren, a doctoral candidate in the research group.

Accordingly, people could experience age-related complications much earlier in life; therefore properly treating and managing stress and/or depression may significantly impact the quality of life throughout the lifetime.

Depression and Chronic Stress Accelerates Aging
Telomere

© www.mentalhealthblog.com

August 7, 2011

Sunday, August 07, 2011
According to Larry D. Rosen, PhD, professor of psychology at California State University, Dominguez Hills, the effects of social media are becoming more and more visible.

Some of their findings suggest that the more time spent on Facebook is related to a greater tendency toward narcissistic behaviors among teenagers. Also, it has been discovered that young adults that spend excessive amounts of time on Facebook show more signs of other psychological disorders, including antisocial behaviors, mania and aggressive tendencies.

Additionally, studies have revealed that excessive daily use of social media can negatively affect the health of children, preteens and teenagers alike as they are more prone to anxiety, depression and other psychological disorders as well as more susceptible to future general health problems.

Furthermore, it is clear that school grades will suffer when spending too much time on Facebook as valuable study time is lost. “Studies found that middle school, high school and college students who checked Facebook at least once during a 15-minute study period achieved lower grades.”

Besides, some studies suggest that so-called teenage “hyper-social networkers” are more likely to engage in risky behaviors, such as smoking, drinking, drug use, fighting and promiscuity.

Consequently, Rosen claims that parents who secretly monitor their child’s social media usage are wasting their time. Instead he suggests that active, but overt, monitoring and open communication about appropriate usage is the key so that when questions or issues arise such as bullying, a child will feel comfortable communicating with their parents. This active role could prevent serious consequences such as depression, anxiety or even suicide. It is also important for parents to stay abreast with online trends and the latest technologies, websites and applications.

On the other hand, research has shown that, despite the numerous negative effects, Facebook can help young adults to express their virtual empathy and facilitate socialization among introverted teens. Also, “social networking can provide tools for teaching in compelling ways that engage young students.”

It seems, like most things in life, everything in moderation is best.

Social Networking's Good and Bad Impacts On Kids
Texting and Social Websites Associated With Risky Behaviors Among Teens

© www.mentalhealthblog.com

August 22, 2010

Sunday, August 22, 2010

Ketamine is a fast-acting liquid anesthetic used mainly by veterinarians; it's also used in human medicine, even in children, because it doesn't depress breathing.

It's also an illegal club drug, known as "special K" or "vitamin K."

The street version is usually sold in a powder form that can be snorted or mixed into drinks, or dissolved into a liquid and injected.

It acts like LSD, causing vivid hallucinations in users and a sensation of floating outside their bodies.
Researchers at Yale University have discovered that a single dose of ketamine helps the brain to form new synaptic connections between neurons and can begin to relieve depressive symptoms in a little as 40 minutes.

In contrast, Prozac and other types of antidepressants can take anywhere from two weeks to a full month before they start to demonstrate any real results, in which benefits can only be seen in about a third of patients. This new antidepressant is now being tested in Canada with promising results.

Dr. James Kennedy, director of the neuroscience research department at the Centre for Addiction and Mental Health in Toronto states that ketamine might alleviate what has been known as a “major clinical problem”. The 2 - 4 weeks that patients await relief is a critical time where devastating outcomes, such as suicide, can occur because they begin to feel more energetic but depressive symptoms remain. Not only is there hope for those with difficult to treat depression, ketamine could actually save lives.
Earlier studies involving patients with "treatment-resistant" depression have found that those given a single dose of ketamine experience rapid and significant improvement in symptoms.

In a small study published earlier this month on patients with bipolar depression, 71 per cent of participants responded to ketamine versus six per cent who responded to placebo.
In addition to being fast-acting, studies show that relief can last for 7 – 10 days, according to professor of psychiatry and neurobiology at Yale, Ronald Duman, who calls ketamine a “magic drug”.

Duman also believes that this so-called magic drug may be able to reverse the effects of stress on the brain by repairing damaged connections between neurons caused by chronic stress.

Although ketamine may not be the ideal long-term solution for treating depression, it could certainly lead to the development of similar compounds that may produce the same effect, but can be more easily administered with less potential for abuse.

"Imagine someone who is in the ER (emergency department) and is highly suicidal. It would be a way to decrease the suicidal risk" says Dr. Pierre Blier, director of mood disorders research at the Institute of Mental Health Research and Canada Research Chair in Psychopharmacology at the Royal Ottawa Mental Health Centre, who has started using ketamine on some of his patients.

Sources:
'Magic drug' gives hope to bipolar patients - Ketamine is mainly used as an anesthetic by vets but shows promise in treating depression

© www.mentalhealthblog.com

June 30, 2010

Wednesday, June 30, 2010
A new study published in the Journal of Clinical Psychiatry has revealed that Omega-3 supplements can be an effective method of treating major depression in patients who do not have anxiety disorders.

At first glance, the efficacy of Omega-3 was not clearly demonstrated; however with further analysis it was clear that Omega-3 improved depressive symptoms as efficiently as those treated with antidepressants.

The experiment studied 432 male and female subjects with major depression over a period of 8 weeks, from October 2005 to January 2009. Each day of the study, half of the participants were given three capsules of OM3 Emotional Balance, a fish oil supplement which contains 1050 mg of eicosapentaenoic acid (EPA) and 150 of docosahexaenoic acid (DHA). The remaining participants took three identical capsules containing sunflower oil, which was flavored with fish oil to maintain the anonymity of the placebos. Researchers ensured a double-blind effect where neither subject nor researcher could identify either group.
“In contrast with typical clinical studies designed to assess the effectiveness of antidepressants, this study included a high proportion of patients with complex and difficult-to-treat conditions, including patients resistant to conventional antidepressant treatments and patients also suffering from an anxiety disorder. The aim was to assess the value of Omega-3 supplementation in a group of individuals more like those treated in outpatient clinics.”
Statistics show that roughly 11% of men and 16% of women in Canada are likely to suffer from major depression at some point in their lives. Currently, depression is listed as the world’s fourth leading cause of death and it is anticipated that it could be the second by the year 2020.
“Epidemiological and neurobiological studies have suggested that a relative deficit in polyunsaturated fatty acids of the Omega-3 group may predispose individuals to psychological disorders such as depression.”
Supplements are likely to be more attractive alternatives to the many patients with depression that cease pharmacotherapy after only a few months because of their fear of stigmatization or side effects. These alternatives need to be more adequately studied so that new treatments may be developed. Ideally, additional research directly comparing Omega-3 with conventional antidepressants could speed up the process toward more effective treatments for depression.

Treating Depression With Omega-3: Encouraging Results from Largest Clinical Study

© www.mentalhealthblog.com

April 24, 2010

Saturday, April 24, 2010
The Buck Institute for Age Research has been studying the possibility that antidepressants and mood stabilizers, like lithium for example, could have positive effects on stroke victims. The growth of new neurons has been known to diminish the effects of a stroke as well as dramatically improve impaired functions after a stroke, while those types of medications have been found to encourage neurogenesis in rodents.
"What this study shows more convincingly than in the past is that the production of new neurons after stroke is beneficial in rodents," said Buck faculty member and senior author David Greenberg, MD, PhD. "Assuming that neurogenesis is also beneficial in humans, drugs approved by the FDA for other purposes and already shown to promote new neuron growth in rodents might be worth studying as a potential treatment for stroke in humans. For example, antidepressants are often used to treat post-stroke depression, but their potential for improving outcome from stroke itself is less certain."
Researchers compared the size of a stroke and the recovery from stroke in genetically altered mice that either had the ability to grow new neurons or not. It was discovered that mice without the ability to grow new neurons suffered strokes 30% larger; whereas the mice with the ability to grow new neurons showed dramatic improvement of motor functions following a stroke.

Although this new research sounds very exciting, Greenberg cautions that people should not attempt to treat themselves until clear evidence is made official as testing has not been rigorous enough to determine if negative effects exist or whether these positive effects can be seen in humans. Testing these medications that stimulate the growth of neurons could lead to other exciting discoveries for many other age-related disorders, such as Alzheimer’s, Parkinson’s and Huntington’s disease.
“Stroke is the third leading cause of death in the U.S. and is the leading cause of serious long-term disability in this country. Treatments for stroke are limited. Clot busting drugs, which have to be given within hours of the stroke, have been of great benefit to a small number of patients, but stroke is not usually diagnosed in time for them to be used.”
What is a stroke?

A stroke (sometimes called a cerebrovascular accident (CVA)) is the rapidly developing loss of brain function(s) due to disturbance in the blood supply to the brain, caused by a blocked or burst blood vessel. This can be due to ischemia (lack of glucose and oxygen supply) caused by thrombosis or embolism or due to a hemorrhage. As a result, the affected area of the brain is unable to function, leading to inability to move one or more limbs on one side of the body, inability to understand or formulate speech, or inability to see one side of the visual field.

What factors lead to a higher risk of stroke?
  • advanced age
  • hypertension
  • a previous stroke or transient ischemic attack (TIA)
  • diabetes
  • high cholesterol
  • cigarette smoking
  • atrial fibrillation
What are the symptoms of stroke?

Symptoms of a stroke that affects the central nervous system include:
  • hemiplegia and muscle weakness of the face
  • numbness
  • reduction in sensory or vibratory sensation
Generally, the symptoms affect one side of the body and the side affected is typically opposite to the affected brain area.

Symptoms of a stroke that affects the brain stem include:
  • altered smell, taste, hearing, or vision
  • drooping of eyelid and weakness of ocular muscles
  • decreased reflexes (gag, swallow, pupil reactivity to light)
  • decreased sensation and muscle weakness in the face
  • balance problems and nystagmus (involuntary eye movement)
  • altered breathing and heart rate
  • weakness in sternocleidomastoid muscle with an inability to turn the head to one side
  • weakness in tongue (inability to protrude and/or move from side to side)
Symptoms of a stroke that affects the cerebral cortex include:
  • aphasia (inability to speak or understand language from involvement of Broca's or Wernicke's area)
  • apraxia (altered voluntary movements)
  • visual field defect
  • memory deficits (with damage to the temporal lobe)
  • hemineglect (a deficit in attention to and awareness of one side of space is observed when there is damage to the parietal lobe)
  • disorganized thinking, confusion, hypersexual gestures (with damage to the frontal lobe)
  • anosognosia (persistent denial of the existence of a, usually stroke-related, deficit)
Symptoms of a stroke that affects the cerebellum include:
  • trouble walking
  • altered movement coordination
  • vertigo and or disequilibrium
What are the long-term effects?

Disability affects 75% of stroke survivors enough to decrease their employability. Stroke can affect patients physically, mentally, emotionally, or a combination of the three. The results of stroke vary widely depending on size and location of the lesion. Dysfunctions correspond to areas in the brain that have been damaged.

Some of the physical disabilities that can result from stroke include:
  • paralysis
  • numbness
  • pressure sores
  • pneumonia
  • incontinence
  • apraxia (inability to perform learned movements)
  • difficulties carrying out daily activities
  • appetite loss
  • speech loss
  • vision loss
  • pain
  • coma
  • death
Some of the mental disabilities that can result from stroke include:
  • anxiety
  • panic attacks
  • flat affect (failure to express emotions)
  • mania
  • apathy
  • psychosis
  • depression (characterized by lethargy, irritability, sleep disturbances, lowered self esteem, and withdrawal)
  • emotional lability (a rapid switch between emotional highs and lows and an inappropriate expression of emotions
  • speech problems
  • dementia
  • attention and memory problems
  • anosognosia (persistent denial of the existence of a, usually stroke-related, deficit)
  • hemispatial neglect (inability to attend to anything on the side of space opposite to the damaged hemisphere)
  • seizures
All resulting affects of stroke are dependent on the severity of brain damage.

Antidepressants as Treatment Immediately Following a Stroke?
Stroke

© www.mentalhealthblog.com

February 20, 2010

Saturday, February 20, 2010
A study in the British Medical Journal found that paroxetine, better known as paxil, decreases the benefits of the cancer treating drug tamoxifen. In addition, they found an increased risk of death in breast cancer patients the longer both drugs were taken concurrently.

Tamoxifen is a popular breast cancer treatment that can be taken for up to five years to prevent a recurrence. Conversely, paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is typically used to treat major depression, obsessive-compulsive, panic,social anxiety, and generalized anxiety.

Paroxetine has revealed promise for easing the hot flashes that can occur after cancer treatment. However, this anti-depressant has been known to have side effects such as nausea, somnolence, and sexual problems. This medication is also associated with significant weight gain and adult suicide.

Researchers studied the health records of 2,430 women taking tamoxifen between the years 1993 and 2005. They discovered that roughly 25% or 630 of these women were also taking paroxetine. Of the 1,074 women that died during this period, 374 of them died from breast cancer according to Ontario's cancer registry.
“Tamoxifen is an extremely important drug for breast cancer," said Dr. David Juurlink, a co-author of the study and a scientist at the Institute for Clinical Evaluative Sciences in Toronto. Paroxetine "takes that benefit away by interfering with the body's normal handling of tamoxifen. Specifically, researchers concluded that paroxetine blocks or inhibits an enzyme called cytochrome P450 2D6, which is needed to metabolize tamoxifen into its active form.
Although the evidence suggests that this anti-depressant must be stopped, researchers caution against abruptly ceasing treatment with paroxetine because of withdrawal effects and worsening of depressive symptoms.

Interestingly, the study did not find any increased risk of death among the smaller sample of women taking tamoxifen combined with some other SSRI, such as fluoxetine (Prozac), sertraline (Zoloft), citalopram (Celexa) and venlafaxine (Effexor). However, this smaller sample size may confound the study’s conclusiveness; however it does suggest that attractive alternatives exist.

Furthermore, there are always unanswered questions when it comes to research that focus on health records as several variables are unknown and uncontrolled. That being said, the slightest risk identified should be enough to stop using this medication, especially when there are equally effective substitutes.

Also, in recent news…
“In the first Paxil birth defect trial that resulted in a $2.5 million verdict against GlaxoSmithKline in October 2009, the infant, Lyam Kilker, was born with three heart defects; an atrial septal defect, a ventricular septal defect, and an interrupted aortic arch, after his mother took Paxil while pregnant.”
Antidepressant interferes with breast-cancer drug
Paroxetine
Paxil Birth Defect Trial - Battle of the Experts

© www.mentalhealthblog.com

January 8, 2010

Friday, January 08, 2010
“The Women's Health Initiative (WHI) of the National Institutes of Health followed more than 160,000 postmenopausal U.S. women for up to 15 years, examining risk factors for and potential preventive measures against cardiovascular disease, cancer and osteoporosis.”

The researchers collected data from 136,000 participants that were not taking antidepressant medications when they first began the study. It was noted during their first follow up between one and three years later that roughly 5,500 of those women had begun taking antidepressants. “The research team compared that group's subsequent history of cardiovascular disease with that of participants who had not started taking antidepressants.”

Results showed that the women taking antidepressants had a small, but statistically significant increased risk of stroke and/or death compared to participants declaring that they were not taking antidepressants.

Lead author, Jordan W. Smoller, MD, ScD, of the Massachusetts General Hospital (MGH) Department of Psychiatry, explains that although it is necessary to treat depression because it is a serious illness, it is equally important for older women to discuss their treatment options with their physician before committing to one because of the various risks involved.

The DSM IV defines depression as experiencing feelings of sadness, helplessness and hopelessness. It is a state of low mood and aversion to activity. Episodes of depressed mood are a core feature in various psychological disorders.

Some symptoms of depression can include:
  • Anxiety
  • Sleep disturbances
  • never seem to be enough
  • dullness
  • chronic sadness never seeming to end
  • obsessions
  • shakiness when feeling most down
  • mood swings
Medications used to treat depression:

Tricyclic antidepressants
  • Amitriptyline
  • Imipramine
  • Nortriptyline
  • Desipramine

  • Side effects: Fatigue, dry mouth, blurred vision, light-headedness
Selective serotonin-reuptake inhibitors (SSRI)
  • Fluoxetine
  • Fluvoxamine
  • Sertraline
  • Paroxetine

  • Side effects: Nausea, gastrointestinal upset, sleep disturbances, headache, agitation
Reversible inhibitors of monoamine oxidase:
  • Moclobemide

  • Side effects: Insomnia, headache, constipation
5-HT2 antagonists:
  • Nefazodone

  • Side effects: Fatigue, light-headedness, nausea, headache
Serotonin-norepinephrine reuptake inhibitors:
  • Venlafaxine

  • Side effects: Nausea, agitation, sweating
MAOIs (monoamine oxidase inhibitors):
  • Phenelzine (Nardil)
  • Tranylcypromine (Parnate)
  • Isocarboxazid (Marplan)
  • Selegiline (Emsam)

  • Side effects: Drowsiness, Constipation, Nausea, Diarrhea, Stomach upset, Fatigue, Dry mouth, Dizziness, Low blood pressure, Light-headedness, Decreased urination, Decreased sexual function, Sleep disturbances, Muscle twitching, Weight gain, Blurred vision, Headache, Increased appetite, Restlessness, Shakiness, Trembling, Weakness, Increased sweating
“Depression is a known risk factor for cardiovascular disease and premature death, and one of the reasons that tricyclic antidepressants are used less frequently is their potential for negative effects on heart function. Selective serotonin reuptake inhibitor (SSRI) antidepressants have fewer side effects in general and are known to have aspirin-like effects on bleeding, which could protect against clot-related cardiovascular disorders.”

Although no relationship was established between antidepressant use and heart disease, follow-up appointments nearly six years later indicated that participants using antidepressants had an increased risk of death and those treated with SSRIs had an increased risk of stroke.

Even though results seem frightening it seems to me that further investigation is needed as there are several problems with this study. The researchers have not distinguished whether the problem really lies within the link between antidepressants and cardiovascular disease or depression itself and cardiovascular disease. Prior studies will show that depression has risks that are just as high as those who use antidepressants in this study. If anything, the study may indicate that treatment with antidepressants could exacerbate those risks. After careful review of this study, it seems difficult to place blame on antidepressants, but more could be revealed with further investigation.

Additionally, the study does not specify whether these women were being treated for depression or for anxiety nor is there any indication that lifestyle factors such as stress, smoking or diet have been accounted for. Furthermore, the study is too group-specific; therefore it cannot suggest that results can be generalized to the other populations, such as men or premenopausal women unfortunately.

Despite the lack of concrete evidence, it seems logical that women with cardiovascular risks would benefit from exploring treatment options other than antidepressants, but in the end, for most, the benefits of antidepressants may far outweigh the costs.

Increased Risk of Death, Stroke in Postmenopausal Women Taking Antidepressants, Study Finds
Monoamine Oxidase Inhibitors
Medications for Treating Depression

© www.mentalhealthblog.com

May 27, 2008

Tuesday, May 27, 2008

New research suggests that religious leaders may have been sitting on a potential treatment for depression all along. Even hippies seem to have caught on to the healing powers of incense long before the academic world.

A team of researchers from John Hopkins University and the Hebrew University in Jerusalem studied the psychoactive effects of burning incense. Researcher, Raphael Mechoulam "found that incensole acetate, a Boswellia resin constituent, when tested in mice lowers anxiety and causes antidepressive-like behavior". Specifically, this constituent activates the TRPV3 protein in areas of the brain that are associated with emotions and nerves. These areas are the same as those already being activated by current medication in use for the treatment of depression and anxiety. Evidently, mice bred without this protein were not affected by the incense.

Although, the idea seems rather harmless in comparison to many of the medications on the market at this time, I have to wonder whether or not this might be a better alternative to medication. I am not convinced that this treatment holds much weight when considering the possible health risks associated with daily doses of incense inhalation in order to sufficiently reduce anxiety and depression.

© www.mentalhealthblog.com

February 29, 2008

Friday, February 29, 2008
Finally, there’s more research suggesting the need to reduce the over-medicating of mental illness, specifically depression. The study conducted by Irving Kirsch of the University of Hull discovered that the benefits of anti-depressants, such as fluoxetine (Prozac), venlafaxine (Effexor), nefazodone (Serzone), and paroxetine (Seroxat / Paxil), are dependent upon the severity of the mental illness.

The study used a meta-analysis of data retrieved from trials supplied by the US Food and Drug Administration. “When the data from all of these trials had been put together, the improvement in depression amongst patients receiving the trial drug, as compared to those receiving placebo (dummy tablets), was not clinically significant in mildly depressed patients or even in most patients who suffer from very severe depression” – Article

It comes as no surprise that only a small group of participants actually benefited from their medications, and these patients tended to be those who suffered from severe depression to begin with. The severely depressed reaped fewer benefits from the placebo and more benefits from the actual medication than those less depressed. This not only suggests that anti-depressants serve their purpose for those who are really suffering, but it clearly demonstrates that not everyone needs to be medicated to function. Over-medicating is a serious problem within our society because it does seem easier to slap on a Band-Aid as opposed to working through months or even years of therapy. Unfortunately, the social and monetary cost of clinical therapy does not seem plausible for everyone in our society, however it hardly seems ethical or even productive to convert the depressed into addicts.

In my opinion, medication should always be the last resort when alternative measures are more proficient in treating mental illness.

© www.mentalhealthblog.com

January 22, 2008

Tuesday, January 22, 2008

The University of Tel Aviv has discovered a link between depression and a biological mechanism that affects the olfactory glands in women. Professor Yehuda Shoenfeld of the Faculty of Medicine implies that women who are depressed are simultaneously losing their sense of smell and as a result are wearing more perfume.

This discovery appears to have been derived from research that implies a biological basis for depression found in lupus patients.
In lupus patients and those with other autoimmune diseases, a particle known as an autoantibody attacks the person’s own immune system, appearing in the human body as an aberrant reaction to autoimmune diseases. This particle is a real novelty, says Prof. Shoenfeld. We have found that, when generated, it weakens a person’s sense of smell and can induce the feeling of depression. - article
The research seems to suggest that you can identify those who are depressed simply by the quantity of perfume that they wear. It also provides further evidence for the therapeutic benefits of aromatherapy.

In addition, I would be curious to see how this might affect office policy in many organizations that request to keep perfume and other scents to a minimum. If this study were to materialize into accepted theory, the ban on scented products in the workplace would not only disguise potentially depressed women, but prevent healthy emotional well-being of women by limiting the use of aromatherapy.

© www.mentalhealthblog.com

Popular Posts

Dentalget.com is dental equipment supplier, we provide high quality dental instruments, dental handpiece at a discount price. Free shipping worldwide.

Categories

9/11 AADD Abortion Academic Success Acetylcholine ADD Adderall Addiction ADHD Adult Attention Deficit Disorder Adultery Advertising Aggression Aging Agreeableness AIDS Air Pressure Alcohol Alcohol Abuse Alcohol Dependence Alcoholism alpha-CaM kinase II Altitude Alzheimer's Amphetamine Amygdala Amyloid Amyloid Deposition Anesthesia Anger Anterior Cingulate Cortex Anterograde Amnesia Anti-Depressants Anti-Psychotic Anticholinergic Anticonvulsant Antiepileptic Antioxidants Anxiety Anxious-Avoidant Anxious-Preoccupied Apolipoprotein E Army Aromatherapy Asperger Syndrome Assessment Associative Learning Asthma Attachment Theory Attention Attention Deficit Disorder Attention Deficit Hyperactivity Disorder Autism Autism Spectrum Disorder Autonomic Nervous System Average Sleep Requirements B-type Natriuretic Peptide Babies Balance Behavioral Problems Behaviour Behavioural Impairment Behavioural Therapy Benadryl Bipolar Disorder Blood Clot Blood Pressure Blue Light Blue Light Goggles Body Mass Index Bone Marrow Brain Brain Development Brain Imaging Brain Injury Brain Stem Brain Surgery Breast Cancer Buddhism bullying Bupropion Business C-reactive Protein Calories CAMH Canada Canadian Charter of Rights and Freedoms Cancer Carbohydrates Cardiovascular Disease Care Facilities Caregiver cars Cdk5 Cell Phone Central Nervous System Centre for Addiction and Mental Health Cerebellum Cerebral Amyloid Angiopathy Cerebral Cortex Cerebrospinal Fluid Cerebrovascular Accident Cerebrovascular Insult Chat Rooms Chewing Childhood Disabilities Childhood Disintegrative Disorder Childhood Emotional Neglect Children Chitin Chitosan Cholesterol Choline Chromosome Chronic Pain Syndrome Chronic Stress Circadian Rhythm Cirrhosis Citalopram Classical Conditioning Climate Change Clot-Busting Drug Co-morbidity Cocaine Cognition Cognitive Development Cognitive Impairment Colloquially Brain Attack Coma Communication Device Communication Technology Concentration Concerta Concussion Conflict Confusion Conscientiousness Control Group Coordination Correlation Cortisol Counselling Couples CPAP Crack CRASH-2 CRASH-3 Creativity Criminal Code Cyberbullying Cyberpsychology Cyklokapron Daytrana Death Death Toll Decision-Making Declarative Memory Deep Brain Stimulation Delusion Dementia Dentures Depression Destrostat Deviant Behaviour Dexedrine Dextromethorphan Diabetes Diet Dietary Supplements Diphenhydramine Disability discrimination Dismissive-Avoidant Disorganized Attachment Disorganized Speech Disorientation Dizziness Docosahexaenoic Acid (DHA) Double-Blind Dream Drinking Drowsiness Drug Abuse Drug Dependence Drug Use Drugs DSM DSM-5 Dual Diagnosis Early Onset Alzheimer's Economic Crisis Ecstasy Effexor Ego Eicosapentaenoic Acid (EPA) Elderly Electrical Stimulation Electroconvulsive Therapy Electrodes Email Embitterment Embolic Emotion Emotional Neglect Emotional Problems Emotional Well-Being Employee Enrivonment Enzyme Epilepsy Estrogen Ethics Evolution Experimental Group Extracellular Signal-Regulated Kinase (ERK) Extroversion Facebook Facebook Fan Page Facebook Friends Family Family Therapy Fast Food Father Father Absenteeism Fatherhood FDA Fear Fearful-Avoidant FeelingBetterNow Fetus Fibrin Fish Oil fluoxetine fMRI Focalin Focus Food Fraud Friday Gamma Secretase Genetic Disorders Genetics Ginkgo Biloba Glucose Glutamate Receptor God Gout Guest Blogger Hair Pulling Haiti Hallucination Hallucinogenic Halo Effect Harm-Reduction Headache Healthy Eating Hearing Heart Attack Heart Disease Hematopoietic Stem Cells Hepatitis Hepatitis C Herbal Supplements Hereditary Angioedema Heredity Heroin High Blood Pressure Hippocampus Hockey Homelessness Hormone Housing Hox Genes Hoxb8 Cells Human Rights Hydromorphone Hyper-social Networker Hyperactivity Hypothalamus Illness Impulse Control Impulsivity Inattentiveness Infant Infidelity Inflammation Insecure Attachment Insomnia Instant Messaging Insulin Intellectual Development Intellectual Disability Internet Intracranial Bleeding Introversion Introvert Ischemic Stroke KASPAR Ketamine Ketogenic Kleptomania Laptop Latent Inhibition Learning Learning Disability Leukotrienes Limbic System Lithium Liver Locked-In Syndrome Long Term Memory Long-Term Potentiation Longevity Lupus Lysteda Maestro Rechargeable System Major Depression Mania MAOI Marriage MDMA Medication Meditation Melatonin Memory Memory Loss Memory Task Men Mental Health Mental Health Forum Mental Heath Mental Illness Metadate Metyrapone Mice Microglia Mild Cognitive Impairment (MCI) Mild Traumatic Brain Injury Military Mind-Body Mindless Eating Mitochondria MOHLTC Mood Disorder Morphine Mortality Rates MRI MS-275 Multiple Sclerosis Muscle Weakness music therapy Narcissism Natasha Richardson National Sleep Foundation Natural Disaster Nature/Nurture Nausea Necrosis Neglect Nerve Neuro-imaging Neurobiology Neurodegeneration Neurodegenrative Diseases Neurodevelopment Disorders Neurogenesis Neurological Disease Neuromarketing Neuron Neuropathy Neuroticism Neurotransmitter News Nintendo Wii Non-REM Sleep Nose Nurse Ratched Nutrition Obesity Obessive Compulsive Spectrum Disorder (OCD) Offspring Olfactory Gland OM3 Emotional Balance Omega 3 Ontario Ontario Review Board Ontario Works Opioid Oral Health Organic Ottawa Over-activity Over-Medication Ovulation Oxidative Cell Oxygen Oxytocin p35 Pacemaker Pain Pain Killer Pain Management Pancreatic Polypeptide Pancreatitis Paralysis Paranoia Paraskevidekatriaphobia Parenthood Parents Parkinson's Paroxetine Paxil PDD-NOS perception Perfume Peripheral Nervous System Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Pathway personality traits Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) PET Scan Pharmacology Phobias Physical Health Physiological Plasmin Plasminogen Plasticity Platelet-Activating Factor Politics Post-Concussion Assessment and Cognitive Test (ImPACT) Potassium Ion Channel Poverty Pregnancy Pressure Procedural Memory Promiscuity Prozac PsychBoard.com Psychiatric Ward Psychological Psychological Inventories Psychologist Psychology Psychology Forum Psychology of Eating Psychosis PTED PTSD Public Health Pyromania Quadriplegic Rehab Relationships Reliability Religion REM Research Retigabine Retrograde Amnesia Rett Syndrome Risperdal Ritalin road rage Robot Robotics Rodent Research Rosiglitazone Samsung Satiety Scales Schizophrenia School Screening Secure Attachment Sedatives Seizure Self-Affirmation Intervention Self-Confidence Self-Esteem Self-Integrity Self-Worth Semantic Memory Senior Seroquel Serotonin Serzone Sex Sex Therapy Sexual Orientation Sexual Satisfaction Shock Therapy Sideline Concussion Assessment Test (SCAT2) Sleep Sleep Apnea Sleep Disorders Sleep Quality Sleep Stages Smartphone Smoking Snacking Sniffing Technology Social Assistance Social Deficits Social Isolation Social Media Social Network Social Rejection Social Skills Social Worker Socialization Societal Change Soft Palate Soldier Somatic Nervous System Spatial Memory Special K Speech Spinal Cord Spinal Cord Injury Spinal Tap Sports Injury SSRI Statin Stem Cell Stimulant Strattera Stress Stress Hormone Stroke Substance Abuse Sugar Suicide Superstition Support Survey Suspicious Tablet Talk Therapy Tamoxifen Tanorexia Tax Payer Technology Television Telomere Temperature Testosterone Texting Therapy Thorazine Threshold Thrombosis Thrombotic Tinnitus Tissue Plasminogen Activator Topographical Disorientation Tranexamic Acid Trauma Treatment Tremors Trial Tribunal Trichotillomania Type-2 Diabetes Vagus Nerve Validity Ventromedial Prefrontal Cortex Video Games Virtual Reality Vision Visual Attention Vitamin B Vitamins Vitiligo Voice Vyvanse Walnuts Weight Loss Welfare Wellbutrin Wernicke–Korsakoff syndrome Wet Brain White Blood Cells Women Work World Health Organization Zileuton Zyban Zyprexa µ-opiate receptors (MOR)